ProQR to Present at Upcoming Scientific Meeting and Investor Conference Press release LEIDEN, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 06, 2018
ProQR to Present at EuroTIDES Conference Press release LEIDEN, The Netherlands, Oct. 31, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 31, 2017
ProQR to Present at Scientific and Investor Conferences in September Press release LEIDEN, the Netherlands, Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 06, 2016
ProQR Announces Expert Perspectives Conference Call Series Press release … x-linked retinitis pigmentosa, Usher syndrome type 2, Leber congenital amaurosis due to CEP290 mutations and Usher syndrome type 1c … June 12, 2020
ProQR Announces R&D Day and Provides Update on Innovation Portfolio Press release First Investor R&D Day on March 14, 2016 in New York, NY November 30, 2015
ProQR Announces Enrollment Has Started in Global Phase 1b Study of QR-010 in Cystic Fibrosis Patients Press release LEIDEN, the Netherlands, June 26, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 26, 2015
On a Shared Quest to Find Treatments for Rare Diseases, ProQR Supports Rare Disease Day Press release LEIDEN, the Netherlands, Feb. 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. February 27, 2017
ProQR Announces Clinical Data Presentations and Investor & Analyst Event at NACFC Press release LEIDEN, the Netherlands, Sept. 27, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 27, 2016
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa Press release Key Updates November 29, 2017
ProQR Receives Fast Track Designation from FDA for QR-010 for Cystic Fibrosis Press release LEIDEN, the Netherlands, July 19, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. July 19, 2016